Immunomedics' Trodelvy Will Be First ADC For Triple-Negative Breast Cancer
Trodelvy was granted an accelerated approval by the US FDA based on a Phase II study. It is the first commercial product for Immunomedics.
You may also be interested in...
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.